http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20130109874-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d0fc2b70675ee19bd5fc464f5ae9061
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-08
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-97
filingDate 2012-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_690ecd66d6896b0da1e55ed761a474cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2ed971d08edbaf49c56a914f6e80890
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98119cd11024955f616c14ae9553cc37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73879f38c75478458b5b8fc3132efdf5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0205f3495f5cbe1ea0a4c863131344f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e981ed0b3439b87c8efa1d7a0f56cf74
publicationDate 2013-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-20130109874-A
titleOfInvention Crosslinking inhibitor of the final glycation end product containing disubstituted acid as an active ingredient and disintegrant
abstract The present invention relates to a crosslinking inhibitor and a disintegrant pharmaceutical composition containing chebulic acid as an active ingredient, inhibiting the formation of crosslinks between the final glycation product and the protein and decomposing the formed crosslinks. According to the present invention, since chebulic acid not only inhibits the formation of cross-links between the already formed final glycated product and the protein, but also has an effect of degrading, it inhibits the structural change of proteins such as collagen and elastin in tissues. And improve and thereby reduce or treat the incidence of the disease.
priorityDate 2012-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419487834
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP15502
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68772216
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ99372
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3565413
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID13717
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526468
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID33727
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP07916
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414886086
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID103183906
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID756
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP04985
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8272
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID155022
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID155022
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71308174
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP54320
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2146
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID4363005
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419509921
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25043
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2006
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19732
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3565880
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425769382
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO01945
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID173839
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP11547
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449915478

Total number of triples: 50.